SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

PALI-2108

PALI·PALISADE BIO, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2b
Time to market
If Phase 2b succeeds, PALI-2108 would need to advance to Phase 3 trials and then file for FDA approval, a process that typically takes several more years. The earliest potential approval would likely be 2029-2030 at the earliest, assuming successful trials.
Why 4/10
The next hard, dated catalyst is the Phase 2b ASCENTRA-UC topline results expected in Q4 2027, roughly 12 months away. Since this is a mid-stage (Phase 2b) drug whose next binary readout is approximately 12 months out, and the drug is the company's sole clinical-stage asset, the impact score is moderate at 4.
Actionable Insight NEUTRAL

The next major catalyst is the Phase 2b ASCENTRA-UC topline data expected in Q4 2027, roughly 12 months away. Positive data would validate PALI-2108's differentiated gut-targeted PDE4 approach in a large, well-controlled study; negative or mixed results would severely impact the stock since PALI-2108 is the company's only clinical-stage asset. Interim milestones to watch include ASCENTRA-CD (Crohn's) first patient dosing targeted for Q1 2027 and any early data presentations at medical conferences.

Price Chart

Loading chart...

Executive Summary

PALI-2108 is Palisade Bio's (NASDAQ: PALI) only clinical-stage asset, an oral, gut-activated PDE4 inhibitor prodrug in development for ulcerative colitis (UC) and Crohn's disease. The company recently dosed the first patient in the global Phase 2b ASCENTRA-UC trial (~204 patients) with topline results expected in Q4 2027, and received FDA clearance for a Phase 2a ASCENTRA-CD trial in Crohn's disease (first patient dosing targeted Q1 2027). Phase 1b data showed 100% clinical response in a small UC cohort and a favorable safety profile across 89 subjects. The stock trades around $1.14 with a mean analyst price target of $9.80, and major institutions like BlackRock and Point72 have been accumulating shares. However, the drug is still years from potential commercialization, the IBD market is highly competitive, and the company will likely need additional financing.

How It Works

PALI-2108 is a prodrug, meaning it is an inactive compound that becomes active only after being processed by bacteria in the gut (specifically in the terminal ileum and colon). Once activated, it inhibits an enzyme called PDE4, which reduces inflammation in the intestinal lining. Because activation happens locally in the gut rather than throughout the body, the drug is designed to treat inflammatory bowel diseases like ulcerative colitis and Crohn's disease with fewer whole-body side effects than traditional PDE4 inhibitors.

Trial Status

The Phase 2b ASCENTRA-UC trial (ulcerative colitis) dosed its first patient in October 2026 and is enrolling up to 204 patients across North America and Europe, with 12-week topline results expected in Q4 2027. A Phase 2a ASCENTRA-CD trial (Crohn's disease) received FDA clearance in September 2026 and is expected to begin dosing in Q1 2027. Phase 1 studies completed across 89 subjects showed favorable safety, differentiated pharmacokinetics, and early clinical activity including 100% clinical response in a small UC cohort.

The Two-Sided Case

▲ Bull Case4
PALI-2108 is a gut-activated PDE4 inhibitor prodrug designed to deliver anti-inflammatory activity locally in the colon while avoiding systemic side effects that have plagued other PDE4 inhibitors like Otezla (apremilast). This differentiated mechanism could offer a better-tolerated oral option in the large IBD market.
Phase 1b data showed 100% clinical response in a small UC cohort, favorable safety across 89 subjects, and rapid (within 7 days) localized target engagement with suppression of inflammatory gene programs, supporting the Phase 2 rationale.
Analyst consensus is overwhelmingly positive: 10 Buy/Strong Buy vs 1 Hold, with a mean price target of $9.80 (roughly 7x the current ~$1.14 stock price). Firms include Oppenheimer, Stifel, B. Riley, Piper Sandler, and Raymond James.
Major institutional investors have been accumulating: BlackRock doubled its position to ~10.4M shares, Point72 doubled to ~5.3M shares, and Citadel doubled to ~1M shares in Q2 2026. A director also bought $14,600 worth of stock in October 2026.
▼ Bear Case4
PALI-2108 is still in Phase 2b, and the IBD market is crowded with approved biologics (Entyvio, Stelara, Skyrizi) and small molecules (Xeljanz, Rinvoq). Even if Phase 2b succeeds, the drug faces a long, expensive path to approval with high risk of failure.
The company is a clinical-stage biotech with no approved products or revenue. It will likely need to raise additional capital through dilutive equity offerings to fund the Phase 2b and Phase 2a trials, which could pressure the stock.
Phase 1b data, while showing 100% clinical response in a small UC cohort, came from a tiny sample size (single cohort) and may not replicate in the larger, placebo-controlled Phase 2b trial.
The stock trades near its 52-week low of $1.08, and the 52-week high was only $2.86, suggesting limited institutional conviction despite recent analyst initiations.

Upcoming Catalysts

  • Phase 2b ASCENTRA-UC topline results expected Q4 2027 (primary binary catalyst)
  • Phase 2a ASCENTRA-CD first patient dosing targeted Q1 2027
  • Potential data presentations at medical conferences (UEG Week, DDW, etc.)
  • Any partnership or licensing announcements for PALI-2108

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PALISADE BIO, INC. 8-K PALI ·Originating report

Sources · 10

Hover a chip for the title
1 markets.businessinsider.com2 markets.businessinsider.com3 seekingalpha.com4 nasdaq.com5 nasdaq.com6 markets.businessinsider.com7 rttnews.com8 morningstar.com9 seekingalpha.com10 streetinsider.com